Advertisement

Rheumatology International

, Volume 35, Issue 5, pp 777–785 | Cite as

Clinical management algorithm of uveitis associated with juvenile idiopathic arthritis: interdisciplinary panel consensus

  • Rosa BouEmail author
  • Alfredo Adán
  • Fátima Borrás
  • Beatriz Bravo
  • Inmaculada Calvo
  • Jaime De Inocencio
  • Jesús Díaz
  • Julia Escudero
  • Alex Fonollosa
  • Carmen García de Vicuña
  • Victoria Hernández
  • Rosa Merino
  • Jesús Peralta
  • María-Jesús Rúa
  • Pilar Tejada
  • Jordi Antón
Review Article - Recommendations and Guidelines

Abstract

Uveitis associated with juvenile idiopathic arthritis (JIA) typically involves the anterior chamber segment, follows an indolent chronic course, and presents a high rate of uveitic complications and a worse outcome as compared to other aetiologies of uveitis. Disease assessment, treatment, and outcome measures have not been standardized. Collaboration between pediatric rheumatologists and ophthalmologists is critical for effective management and prevention of morbidity, impaired vision, and irreparable visual loss. Although the Standardization of Uveitis Nomenclature Working Group recommendations have been a great advance to help clinicians to improve consistency in grading and reporting data, difficulties arise at the time of deciding the best treatment approach in the individual patient in routine daily practice. For this reason, recommendations for a systematized control and treatment strategies according to clinical characteristics and disease severity in children with JIA-related uveitis were developed by a panel of experts with special interest in uveitis associated with JIA. A clinical management algorithm organized in a stepwise regimen is here presented.

Keywords

Algorithm Biologic therapy Corticosteroids Juvenile idiopathic arthritis Methotrexate Uveitis 

Notes

Acknowledgments

The authors thank Marta Pulido, MD, for editing the manuscript and editorial assistance.

Conflict of interest

RB declares that she has received speakers’ bureau fees from Novartis and Abbvie, and travel and expense payments from Abbvie, Pfizer and Novartis. JA. declares that his institution has received a PI grant from Pfizer and that he has received speakers’ bureau fees from Pfizer, Roche, and GEBRO, and speakers’ bureau fees and travel and expense payments from Abbvie. All other authors declare that they do not have competing interests. Meetings to reach consensus were funded by Abbvie through an unrestricted grant.

References

  1. 1.
    Carvounis PE, Herman DC, Cha S, Burke JP (2006) Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 244:281–290CrossRefPubMedGoogle Scholar
  2. 2.
    Sabri K, Saurenmann RK, Silverman ED, Levin AV (2008) Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS 12:539–545CrossRefPubMedGoogle Scholar
  3. 3.
    Heiligenhaus AI, Niewerth M, Ganser G, Heinz C, Minden K (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46:1015–1019CrossRefGoogle Scholar
  4. 4.
    De Boer J, Wulffraat N, Rothova A (2003) Visual loss in uveitis of childhood. Br J Ophthalmol 87:879–884CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Bou R, Iglesias E, Antón J (2014) Treatment of uveitis in juvenile idiopathic arthritis. Curr Rheumatol Rep 16:437. doi: 10.1007/s11926-014-0437-4 CrossRefPubMedGoogle Scholar
  6. 6.
    Heiligenhaus A, Foeldvari I, Edelsten C, Smith JR, Saurenmann RK, Bodaghi B, de Boer J, Graham E, Anton J, Kotaniemi K, Mackensen F, Minden K, Nielsen S, Rabinovich EC, Ramanan AV, Strand V (2012) Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken) 64:1365–1372CrossRefGoogle Scholar
  7. 7.
    Cassidy J, Kivlin J, Lindsley C, Nocton J (2006) Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 117:1843–1845CrossRefPubMedGoogle Scholar
  8. 8.
    Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516CrossRefPubMedGoogle Scholar
  9. 9.
    Chylack LT Jr, Leske MC, McCarthy D, Khu P, Kashiwagi T, Sperduto R (1989) Lens opacities classification system II (LOCS II). Arch Ophthalmol 107:991–997CrossRefPubMedGoogle Scholar
  10. 10.
    Nussenblatt RB, Palestine AG, Chan CC, Roberge F (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92:467–471CrossRefPubMedGoogle Scholar
  11. 11.
    Samudre SS, Lattanzio FA Jr, Williams PB, Sheppard JD Jr (2004) Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther 20:533–547CrossRefPubMedGoogle Scholar
  12. 12.
    Thorne JE, Woreta FA, Dunn JP, Jabs DA (2010) Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 117:1436–1441CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Lovasik JV (1986) Pharmacokinetics of topically applied cyclopentolate HCl and tropicamide. Am J Optom Physiol Opt 63:787–803CrossRefPubMedGoogle Scholar
  14. 14.
    Foeldvari I, Wierk A (2005) Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 32:362–365PubMedGoogle Scholar
  15. 15.
    Heiligenhaus A, Mingels A, Heinz C, Ganser G (2007) Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 17:743–748PubMedGoogle Scholar
  16. 16.
    Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T, Baus H, Becker M, Bertram B, Dannecker G, Deuter C, Foeldvari I, Frosch M, Ganser G, Gaubitz M, Gerdes G, Horneff G, Illhardt A, Mackensen F, Minden K, Pleyer U, Schneider M, Wagner N, Zierhut M (2012) Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 32:1121–1133CrossRefPubMedGoogle Scholar
  17. 17.
    Ferrante P, Ramsey A, Bunce C, Lightman S (2004) Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 32:563–568CrossRefGoogle Scholar
  18. 18.
    Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F (2013) Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol 40:74–79CrossRefPubMedGoogle Scholar
  19. 19.
    Kotaniemi K, Säilä H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5:1425–1429CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575–1578CrossRefPubMedGoogle Scholar
  21. 21.
    García-De-Vicuña C, Díaz-Llopis M, Salom D, Bou R, Díaz-Cascajosa J, Cordero-Coma M, Ortega G, Ortego-Centeno N, Suarez-De-Figueroa M, Cruz-Martínez J, Fonollosa A, Blanco R, García-Aparicio ÁM, Benítez-Del-Castillo JM, Antón J (2013) Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. doi: 10.1155/2013/560632 PubMedCentralPubMedGoogle Scholar
  22. 22.
    Mok CC, van der Kleij D, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol 32:1429–1435CrossRefPubMedGoogle Scholar
  23. 23.
    Murias S, Alcobendas R, Pascual-Salcedo D, Remesal A, Peralta J, Merino R (2014) Anti-adalimumab antibodies in paediatric rheumatology patients: a pilot experience. Rheumatology (Oxford) 53:2124–2126CrossRefGoogle Scholar
  24. 24.
    Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML (2013) High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol 40:1749–1755CrossRefPubMedGoogle Scholar
  25. 25.
    Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD, Rosenbaum JT (2009) Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 127:819–822PubMedGoogle Scholar
  26. 26.
    Richards JC, Tay-Kearney ML, Murray K, Manners P (2005) Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 33:461–468CrossRefGoogle Scholar
  27. 27.
    Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66:548–550CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, Cimino L, Zannin ME (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62:821–825CrossRefGoogle Scholar
  29. 29.
    Tappeiner C, Heinz C, Ganser G, Heiligenhaus A (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol 39:1294–1295CrossRefPubMedGoogle Scholar
  30. 30.
    Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV, Pelegrín L (2013) Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 251:2627–2632CrossRefPubMedGoogle Scholar
  31. 31.
    Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50:1390–1394CrossRefGoogle Scholar
  32. 32.
    William M, Faez S, Papaliodis GN, Lobo AM (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2:231–233. doi: 10.1007/s12348-012-0081-y CrossRefPubMedCentralPubMedGoogle Scholar
  33. 33.
    Heiligenhaus A (2006) When should intraocular lenses be implanted in patients with juvenile idiopathic arthritis-associated iridocyclitis? Ophthalmic Res 38:316–317CrossRefPubMedGoogle Scholar
  34. 34.
    Grajewski RS, Zurek-Imhoff B, Roesel M, Heinz C, Heiligenhaus A (2012) Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis. Acta Ophthalmol 90:657–662CrossRefPubMedGoogle Scholar
  35. 35.
    Adán A, Gris O, Pelegrín L, Torras J, Corretger X (2009) Explantation of intraocular lenses in children with juvenile idioapathic arthritis-associated uveítis. J Cataract Refract Surg 35:603–605CrossRefPubMedGoogle Scholar
  36. 36.
    Bohnsack BL, Freedman SF (2013) Surgical outcomes in childhood uveitic glaucoma. Am J Ophthalmol 155:134–142CrossRefPubMedGoogle Scholar
  37. 37.
    Kotaniemi K, Sihto-Kauppi K (2007) Occurrence and management of ocular hypertension and secondary glaucoma in juvenile idiopathic arthritis-associated uveitis: an observational series of 104 patients. Clin Ophthalmol 1:455–459PubMedCentralPubMedGoogle Scholar
  38. 38.
    Najjar DM, Cohen EJ, Rapuano CJ, Laibson PR (2004) EDTA chelation for calcific band keratopathy: results and long-term follow-up. Am J Ophthalmol 137:1056–1064CrossRefPubMedGoogle Scholar
  39. 39.
    Mackensen F, Heinz C, Becker MD, Heiligenhaus A (2008) Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28:41–45CrossRefPubMedGoogle Scholar
  40. 40.
    Cervantes-Castañeda RA, Giuliari GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K, Foster CS (2009) Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 19:622–629PubMedGoogle Scholar
  41. 41.
    Adán A, Pelegrín L, Rey A, Llorenç V, Mesquida M, Molins B, Ríos J, Keller J (2013) Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 33:1435–1440CrossRefPubMedGoogle Scholar
  42. 42.
    Yu EN, Paredes I, Foster CS (2007) Surgery for hypotony in patients with juvenile idiopathic arthritis-associated uveitis. Ocul Immunol Inflamm 15:11–17CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Rosa Bou
    • 1
    Email author
  • Alfredo Adán
    • 3
  • Fátima Borrás
    • 5
  • Beatriz Bravo
    • 6
  • Inmaculada Calvo
    • 7
  • Jaime De Inocencio
    • 8
  • Jesús Díaz
    • 2
  • Julia Escudero
    • 5
  • Alex Fonollosa
    • 10
  • Carmen García de Vicuña
    • 2
  • Victoria Hernández
    • 4
  • Rosa Merino
    • 12
  • Jesús Peralta
    • 13
  • María-Jesús Rúa
    • 11
  • Pilar Tejada
    • 9
  • Jordi Antón
    • 1
  1. 1.Pediatric Rheumatology UnitUniversitat de BarcelonaBarcelonaSpain
  2. 2.Ophthalmology Department, Hospital Sant Joan de DéuUniversitat de BarcelonaBarcelonaSpain
  3. 3.Ophthalmology Department, Hospital ClínicUniversitat de BarcelonaBarcelonaSpain
  4. 4.Rheumatology Department, Hospital ClínicUniversitat de BarcelonaBarcelonaSpain
  5. 5.Ophthalmology DepartmentHospital Universitario Carlos HayaMálagaSpain
  6. 6.Pediatric Rheumatology UnitHospital Universitario Virgen de las NievesGranadaSpain
  7. 7.Pediatric Rheumatology UnitHospital Universitario La FeValenciaSpain
  8. 8.Pediatric Rheumatology UnitHospital Universitario 12 de OctubreMadridSpain
  9. 9.Ophthalmology DepartmentHospital Universitario 12 de OctubreMadridSpain
  10. 10.Ophthalmology DepartmentHospital de CrucesBilbao-BarakaldoSpain
  11. 11.Pediatric Rheumatology UnitHospital de CrucesBilbao-BarakaldoSpain
  12. 12.Pediatric Rheumatology UnitHospital Universitario La PazMadridSpain
  13. 13.Ophthalmology DepartmentHospital Universitario La PazMadridSpain

Personalised recommendations